NDATF (NDatalyze) YoY EBITDA Growth: 0.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NDatalyze YoY EBITDA Growth?

NDatalyze NDATF YoY EBITDA Growth is 0.00% as of May. 2026. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NDatalyze's YoY EBITDA Growth for the quarter that ended in May. 2026 was 0.00%.

NDatalyze's EBITDA per Share for the three months ended in May. 2026 was $-0.00.

NDatalyze YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for NDatalyze's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NDatalyze YoY EBITDA Growth Chart

NDatalyze Annual Data
Trend Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
YoY EBITDA Growth
Get a 7-Day Free Trial -19.05 4.00 66.67 -37.50 72.73

NDatalyze Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.00 66.67 -200.00 80.00 0.00

NDatalyze YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NDatalyze's YoY EBITDA Growth for the fiscal year that ended in Feb. 2026 is calculated as:

YoY EBITDA Growth (A: Feb. 2026 )
=(EBITDA per Share (A: Feb. 2026 )-EBITDA per Share (A: Feb. 2025 ))/ | EBITDA per Share (A: Feb. 2025 ) |
=(-0.003--0.011)/ | -0.011 |
=72.73 %

NDatalyze's YoY EBITDA Growth for the quarter that ended in May. 2026 is calculated as:

YoY EBITDA Growth (Q: May. 2026 )
=(EBITDA per Share (Q: May. 2026 )-EBITDA per Share (Q: May. 2025 )) / | EBITDA per Share (Q: May. 2025 )) |
=(-0.001--0.001)/ | -0.001 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
NDatalyze (NDATF) has a YoY EBITDA Growth of 0.00% as of May. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NDatalyze and its competitors.
Is NDatalyze's YoY EBITDA Growth too high?
NDatalyze's current YoY EBITDA Growth is 0.00%.
How does NDatalyze's YoY EBITDA Growth compare to VEEV and BTSG?
NDatalyze's YoY EBITDA Growth of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NDatalyze and its competitors. NDatalyze's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NDatalyze stock overvalued right now?
NDatalyze (NDATF) has a current YoY EBITDA Growth of 0.00%. The stock's GF Value™ is $0.05, compared to a current price of $0.08 — trading 60% above its estimated fair value. The current YoY EBITDA Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For NDatalyze (NDATF), the current YoY EBITDA Growth is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NDatalyze Business Description

Other Exchanges NDAT:Canada
Address 707 - 7th Avenue SW, Suite 1150, Calgary, AB, CAN, T2P 3H6
NDatalyze Corp develops technologically-based, specialized products, databases, and applications. The YMI division is developing a data-driven consumer mHealth application designed to predict current and future health conditions to lessen the cost of health services and decrease the load on health care services. The MLdelic division is providing a database platform that may be used to predict potential benefits associated with the use of entheogenic compounds within the mental health sector. The Medxtractor division manufactures small-scale bio-extractors that are used to extract essential oils from botanical materials.